You are here

Prices & Quotes - UK Markets - Oxford Biomedica (OXB)

Risk Warning The value of investments can fall as well as rise and any income from them is not guaranteed and you may get back less than you invested. Past performance is not a guide to future performance.

Share Price:
Down 909.00p
Change Today:
-47.00p
Market Cap:
783.33m
Sector:
Pharmaceuticals & Biotechnology

ShareCast News

Liberum hikes target price on Oxford Biomedica 28-Apr-2020 ShareCast
Oxford Biomedica joins Covid-19 vaccine consortium 08-Apr-2020 ShareCast
Novo Holdings pours ?53.5m into Oxford Biomedica 28-May-2019 ShareCast
Friday broker round-up 15-Mar-2019 ShareCast
Oxford Biomedica swings to positive earnings in ... 14-Mar-2019 ShareCast
Oxford Biomedica enters research collaboration w... 12-Mar-2019 ShareCast
Oxford BioMedica forms new digital framework ini... 23-Nov-2018 ShareCast
First patient successfully dosed with Oxford Bio... 25-Oct-2018 ShareCast
'Transformative year' sees Oxford Biomedica prof... 13-Sep-2018 ShareCast
Oxford Biomedica could be in line for larger roy... 18-Jul-2018 ShareCast
Oxford BioDynamics' 'diagnostic potential' revea... 26-Jun-2018 ShareCast
Oxford Biomedica 'fully valued' as Jefferies ups... 13-Jun-2018 ShareCast
Wednesday broker round-up 13-Jun-2018 ShareCast
Sunday share tips: Oxford BioMedica, Avast, Sava... 10-Jun-2018 ShareCast
Oxford Biomedica inks licensing agreement with A... 06-Jun-2018 ShareCast
Oxford BioMedica reaps rewards of Novartis' FDA ... 02-May-2018 ShareCast
Oxford Biomedica announces placing to inject 20... 09-Mar-2018 ShareCast
Oxford BioMedica signs collaboration agreement w... 15-Feb-2018 ShareCast
Boost for Oxford Biomedica as Novartis files for... 31-Oct-2017 ShareCast
Sunday newspaper round-up: London Fisheries Conv... 02-Jul-2017 ShareCast
Oxford BioMedica's RetinoStat achieves 'favourab... 10-Oct-2016 ShareCast
Oxford Biomedica to raise 8.1m in placing 23-Feb-2016 ShareCast
Oxford Biomedica signs 'transformational' new co... 03-Nov-2014 ShareCast
Friday broker round-up UPDATE 10-Oct-2014 ShareCast
Friday broker round-up UPDATE 11-Apr-2014 ShareCast
Oxford BioMedica posts 12.1m pound loss 10-Apr-2014 ShareCast
Oxford BioMedica wins green light to resume clin... 17-Oct-2013 ShareCast
Directors at Thorntons top up as profits return 12-Sep-2013 ShareCast
Thursday broker round-up UPDATE 12-Sep-2013 ShareCast
Oxford Biomedica wins significant government fun... 11-Sep-2013 ShareCast
Oxford BioMedica receives million dollar milesto... 28-Aug-2013 ShareCast
Qualye Munro director buys 3.3 per cent stake ah... 16-Jul-2013 ShareCast
Signet CFO sells amid share-price strength 20-Jun-2013 ShareCast
Oxford Instruments lifts annual profit 11-Jun-2013 ShareCast
Oxford Biomedica Chief Scientific Officer steps ... 06-Jun-2013 ShareCast
Oxford Biomedica slumps as clinical trial is put... 03-Jun-2013 ShareCast
Monday broker round-up UPDATE 03-Jun-2013 ShareCast
Oxford Biomedica bags Novartis leukaemia deal 01-May-2013 ShareCast
Revenue rises to 7.8m pounds in full year at Oxf... 27-Feb-2013 ShareCast
Oxford BioMedica halts trial due to poor recruit... 10-Oct-2012 ShareCast
Small caps round-up: Brady, Oxford BioMedica, De... 31-Aug-2012 ShareCast
Small Caps round-up: eXpansys, Oxford Biomedica,... 08-Aug-2012 ShareCast
Small caps round-up: Quadrise, Software Radio, M... 08-Jun-2012 ShareCast
Small caps round-up: Sportech, Silverdell, Oxfor... 11-May-2012 ShareCast
Small caps round-up: Omega Diagnostics, Oxford B... 16-Apr-2012 ShareCast
Small caps round-up: Gable, Motive Television, O... 12-Mar-2012 ShareCast
Another director dealing for Dunelm; AZ Electron... 08-Mar-2012 ShareCast
Small caps round-up: Arena, RedHot Media, Vp... 10-Feb-2012 ShareCast
London close: Financials lead the way higher 15-Dec-2011 ShareCast
London midday: Old Mutual and miners provide a l... 15-Dec-2011 ShareCast
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

OXB Market Data

Currency UK Pounds
Price 909.00p
Change Today -47.00p
52 Week High 1,634.00p
52 Week Low 905.00p
Volume 166,710
Shares Issued 86.18m
Market Cap 783.33m
Beta 0.03

Performance Indicators

Compare performance with the sector and the market.

Key
Vs Market
Vs Sector
Value
market
  1. full market star
  2. empty market
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. empty sector
  3. empty sector
  4. empty sector
  5. empty sector
Price Trend
market
  1. full market star
  2. half market star
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. empty sector
  4. empty sector
  5. empty sector
Income
Not Available
Growth
market
  1. full market star
  2. full market star
  3. full market star
  4. full market star
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. half sector star
  5. empty sector
Price Chg 6m
market
  1. half market star
  2. empty market
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. empty sector
  3. empty sector
  4. empty sector
  5. empty sector
P/E
Not Available
PEG
market
  1. full market star
  2. full market star
  3. full market star
  4. half market star
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. half sector star
  5. empty sector
Dividend Yield
Not Available
EPS Growth
Not Available
Operating Margin
market
  1. full market star
  2. half market star
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. half sector star
  4. empty sector
  5. empty sector

What The Brokers Say

Strong Buy 5
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 6
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

OXB Dividends

No dividends found

Trades for 21-Jan-2022

Time Volume / Share Price
16:37 15,000 @ 911.95p
16:35 30,499 @ 909.00p
16:29 91 @ 916.00p
16:29 8 @ 916.00p
16:29 8 @ 913.00p

OXB Key Personnel

CEO John Dawson
CFO Stuart Paynter